Imunon, Inc.
CLSN
Clasificación en acciones
#34954
Imunon, Inc. is a biotechnology firm in the clinical development stage,... Imunon, Inc. is a biotechnology firm in the clinical development stage, dedicated to innovating and commercializing DNA-centric immunotherapies, vaccines, and targeted chemotherapy solutions. Its primary pipeline assets include GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a unique formulation of doxorubicin encapsulated in heat-activated liposomes, currently being assessed for a variety of cancer indications. Furthermore, the company is advancing two early-phase platform technologies aimed at developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA treatments. Established in 1982, Imunon, Inc. maintains its operational base in Lawrenceville, New Jersey.
Precio por acción
$1.96
Última sincronización: 2022-09-20
Capitalización bursátil
$4.46M
Cambio (1 día)
0.00%
Cambio (1 año)
122.70%
País
US
Comercio Imunon, Inc. (CLSN)
Categoría
Healthcare
Ratio P/S de Imunon, Inc. (CLSN)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Imunon, Inc., el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Imunon, Inc. desde 2026 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
